期刊
THERANOSTICS
卷 11, 期 15, 页码 7425-7438出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.60211
关键词
tumor immunotherapy; glycoengineering; tetra acetyl-N-azidoacetyl-mannosamine; Pam3CSK4; PD1/PD-L1
资金
- Bilateral Inter-Governmental S&T Cooperation Project from Ministry of Science and Technology of China [2018YFE0114300]
- National Natural Science Foundation of China [32070752, 81972882, 81772974]
- Natural Science Foundation of Tianjin City [18JCQNJC12600]
The study focused on overcoming the obstacles of tumor-specific antigens and immune tolerance in cancer immunotherapy. By generating a neoantigen MDP, the researchers were able to enhance the anti-tumor efficacy in murine models of breast cancer and lung cancer, resulting in significant inhibition of tumor growth and prolonged survival. The MDP neoantigen also increased sensitivity to immune checkpoint inhibitors and improved overall response and clinical outcome.
The lack of tumor specific antigens (TSA) and the immune tolerance are two major obstacles for the immunotherapy of cancer. Current immune checkpoint inhibitors (ICIs) show clinical responses in only limited subsets of cancer patients, which, to some extent, depends on the mutation load of tumor cells that may generate neoantigens. Here, we aimed to generate a neoantigen MDP to exhibit stronger anti-tumor efficacy. Methods: In this study, we utilized chemically modified sialic acid precursor tetra acetyl-N-azidoacetyl-mannosamine (AC(4)ManNAZ) to engineer the glycoproteins on the membranes of tumor cells for the covalent ligation of hapten adjuvant Pam3CSK4 in vivo, which eventually generated a neoantigen, i.e., ManNAZ-DBCO-Pam3CSK4 (MDP), on tumor cells. The high labeling efficiency, relatively specific biodistribution in tumor tissues and the anti-tumor efficacy were confirmed in the syngeneic murine models of the breast cancer and the lung cancer. Results: The generation of MDP neoantigen in tumor-bearing mice significantly evoked both the humoral and the T-cell-dependent antitumor immune responses, resulting in a strong inhibition on the growth of the breast cancer and the lung cancer allografts and significantly prolonged survival of tumor-bearing mice. Interestingly, MDP neoantigen was able to dramatically increase the sensitivity of cancer cells to ICIs and greatly enhance the anti-tumor efficacy in the murine models of both breast cancer and the lung cancer, which showed no or low responses to the immunotherapy with anti-PD1 antibody alone. Conclusions: We developed a simple metabolic glycoengineering method to artificially generate neoantigens on tumor cells to enhance tumor cell immunogenicity, which is able to significantly improve the response and the clinical outcome of ICIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据